US Patent

US8846112 — Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation

Method of Use · Assigned to INO Therapeutics LLC · Expires 2029-06-30 · 3y remaining

Vulnerability score 73/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of distributing a pharmaceutical product, specifically inhaled nitric oxide gas, for treating neonates with hypoxic respiratory failure.

USPTO Abstract

Disclosed are methods of distributing a pharmaceutical product comprising nitric oxide gas. The methods include supplying a source of nitric oxide gas to a medical provider, informing the medical provider about a recommended dose of inhaled nitric oxide gas for treatment of neonates with hypoxic respiratory failure, and providing a warning about use of inhaled nitric oxide in patients with pre-existing left ventricular dysfunction.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1286 — Inomax
U-1286 — Inomax

Patent Metadata

Patent number
US8846112
Jurisdiction
US
Classification
Method of Use
Expires
2029-06-30
Drug substance claim
No
Drug product claim
No
Assignee
INO Therapeutics LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.